Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefitinib in Recurrent Colorectal Adenocarcinoma
NCT00025350Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of gefitinib in colorectal adenocarcinoma (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Progression-Free Survival Rate at 4 months, Objective Tumor Response Rate up to 5 years and 2 more. Started Oct 2001; status: completed.
02
Drugs
03
Conditions
colorectal adenocarcinoma
Beyond the preview
Go deeper on NCT00025350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025350.